誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002437 誉衡药业

已收盘 12-18 15:00:00

{"stockData":{"symbol":"002437","market":"SZ","secType":"STK","nameCN":"誉衡药业","latestPrice":3.08,"timestamp":1766041380000,"preClose":3.08,"halted":0,"volume":21767955,"delay":0,"changeRate":0,"floatShares":2098999999,"shares":2232000000,"eps":0.1313,"marketStatus":"已收盘","change":0,"latestTime":"12-18 15:00:00","open":3.06,"high":3.12,"low":3.05,"amount":67350600,"amplitude":0.0227,"askPrice":3.09,"askSize":4283,"bidPrice":3.08,"bidSize":18632,"shortable":0,"etf":0,"ttmEps":0.1313,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":5,"adr":0,"adjPreClose":3.08,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":3.39,"lowLimit":2.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2232028126,"isCdr":false,"pbRate":3.19,"roa":"--","peRate":23.45773,"roe":"11.93%","epsLYR":0.1059,"committee":-0.068656,"marketValue":6875000000,"turnoverRate":0.0104,"status":2,"floatMarketCap":6466000000},"requestUrl":"/m/hq/s/002437/wiki","defaultTab":"wiki","newsList":[{"id":"2592519239","title":"誉衡药业：相关股份尚未完成过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2592519239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592519239?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:12","pubTimestamp":1765933930,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业12月16日在投资者关系平台上答复投资者关心的问题。谢谢誉衡药业回复：您好，根据四川省成都市中级人民法院的公告，竞拍者应于2025年12月6日前将尾款缴纳至法院指定账户，并在2025年12月13日前到法院签署成交确认书等，具体请您参考此前的竞买公告，相关股份尚未完成过户，感谢关注！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700004952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","002437","BK0028","BK0077","BK0060","BK0239","BK0188"],"gpt_icon":0},{"id":"2591861218","title":"誉衡药业(002437)12月10日股东户数10.29万户，较上期减少1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861218","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591861218?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:45","pubTimestamp":1765791930,"startTime":"0","endTime":"0","summary":"证券之星消息，近日誉衡药业披露，截至2025年12月10日公司股东户数为10.29万户，较11月28日减少1300.0户，减幅为1.25%。在化学制药行业个股中，誉衡药业股东户数高于行业平均水平，截至12月10日，化学制药行业平均股东户数为3.49万户。从股价来看，2025年11月28日至2025年12月10日，誉衡药业区间跌幅为1.55%，在此期间股东户数减少1300.0户，减幅为1.25%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0188","BK0239","BK0060","BK0077","BK0028","002437"],"gpt_icon":0},{"id":"2588728511","title":"誉衡药业：截至2025年11月28日股东人数为10.42万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728511?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:54","pubTimestamp":1764579276,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月30日的股东人数是多少，谢谢誉衡药业回复：您好！截至2025年11月28日，公司股东人数为10.42万户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100019994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0077","BK0028","002437","BK0239","BK0095"],"gpt_icon":0},{"id":"2586277071","title":"誉衡药业：佩玛贝特片主要通过靶向PPARα来降低血脂水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2586277071","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586277071?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300976,"startTime":"0","endTime":"0","summary":"甘油三酯水平与肥胖密切相关，可以理解为佩玛贝特片可以降脂吗？与目前降糖、减重的产品司美格鲁肽与替尔泊泰相比，佩玛贝特片的作用机理不同，前两者可以通过抑制食欲，增强饱腹感来控制能量摄入，佩玛贝特片主要通过靶向PPARα来降低血脂水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0077","BK0239","002437","BK0028","BK0095"],"gpt_icon":0},{"id":"2586770252","title":"誉衡药业：西格列汀二甲双胍缓释片依从性更好","url":"https://stock-news.laohu8.com/highlight/detail?id=2586770252","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586770252?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300973,"startTime":"0","endTime":"0","summary":"投资者提问：司美格鲁肽、恩格列净、替尔泊肽均适用于2型糖尿病，公司的降糖类药物西格列汀二甲双胍缓释片也是治疗成人的2型糖尿病。西格列汀二甲双胍缓释片（誉平）是一款复方制剂，在药物作用机制中，复方制剂可以实现药物有效成分协同增效，有效控制血糖。相较于常释片，缓释片依从性更好，一天仅需服用一次。相较于针剂，誉平作为口服片剂更易使用，经济性也有一定优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002437","BK0028","BK0077","BK0188","BK0060","BK0095"],"gpt_icon":0},{"id":"2586277705","title":"誉衡药业：复方头孢克洛胶囊占公司整体营收比例较低","url":"https://stock-news.laohu8.com/highlight/detail?id=2586277705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586277705?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300973,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：目前全国感冒患者持续增加，请问公司的抗感染类药物复方头孢克洛胶囊的销售情况？誉衡药业回复：您好！复方头孢克洛胶囊占公司整体营收比例较低，销量变化与流感的关联度不大。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437"],"gpt_icon":0},{"id":"2586270880","title":"誉衡药业：公司目前没有变更注册地址的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2586270880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586270880?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300972,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的办公地址在北京市顺义区空港开发区，本月司法拍卖后，原控股股东的冻结股份已完全拍卖退出。请问公司后续会不会将注册地址从黑龙江变更为北京？誉衡药业回复：您好！公司股东的变化不会导致公司注册地址变化，公司目前没有变更注册地址的计划。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0077","BK0239","002437","BK0028","BK0095"],"gpt_icon":0},{"id":"2586277043","title":"誉衡药业：安脑丸主要在医院销售部分省份实体药店有售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586277043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586277043?lang=zh_cn&edition=full","pubTime":"2025-11-28 11:36","pubTimestamp":1764300969,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：本人在上海，去周边几家实体药店转了转，问了店员均回复店内无蒲公英安脑丸销售，请问公司有无向实体药店铺货，都铺在哪里？誉衡药业回复：您好！安脑丸是一款处方药，主要应用场景在医院，实体药店只有部分省份在售，如陕西、湖北等。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800012430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","BK0188","BK0028","BK0239","BK0095","002437"],"gpt_icon":0},{"id":"2586831572","title":"誉衡药业：截至2025年11月20日股东人数为10.39万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586831572","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586831572?lang=zh_cn&edition=full","pubTime":"2025-11-26 08:55","pubTimestamp":1764118514,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月20日的股东人数是多少，谢谢誉衡药业回复：您好！截至2025年11月20日，公司股东人数为10.39万户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600004315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0060","BK0188","BK0077","002437","BK0239","BK0028"],"gpt_icon":0},{"id":"2586414518","title":"誉衡药业：该产品仍处在医院开发及上量的窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2586414518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586414518?lang=zh_cn&edition=full","pubTime":"2025-11-25 09:03","pubTimestamp":1764032594,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业11月24日在投资者关系平台上答复投资者关心的问题。谢谢誉衡药业回复：您好！该产品仍处在医院开发及上量的窗口期，公司将在四季度及明年重点关注该产品的销售情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0095","BK0188","BK0028","BK0239","BK0060","002437"],"gpt_icon":0},{"id":"2585614958","title":"誉衡药业（002437）披露董事、高级管理人员通过司法拍卖方式增持公司股份的自愿性披露公告，11月21日股价下跌2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585614958","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585614958?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:25","pubTimestamp":1763735140,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，誉衡药业报收于3.11元，较前一交易日下跌2.81%，最新总市值为69.42亿元。近日，誉衡药业发布关于董事、高级管理人员通过司法拍卖方式增持公司股份的自愿性披露公告。公告显示，公司董事、总经理、财务负责人国磊峰先生及其一致行动人西藏誉磐企业管理合伙企业通过司法拍卖方式合计竞得公司2,500.00万股股份，占公司总股本的1.12%。其中，国磊峰增持2,000.00万股，持股比例由0.98%上升至1.88%；西藏誉磐增持500.00万股，持股比例达0.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0028","BK0188","BK0060","BK0239","002437","BK0077"],"gpt_icon":0},{"id":"2585116648","title":"誉衡药业(002437.SZ)总经理国磊峰及其一致行动人竞拍取得2500万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2585116648","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585116648?lang=zh_cn&edition=full","pubTime":"2025-11-21 17:22","pubTimestamp":1763716963,"startTime":"0","endTime":"0","summary":"智通财经APP讯，誉衡药业 公告，公司股东 Yu Heng International Investments Corporation 持有的公司5677.81万股股票及股东 Oriental Keystone Investment Limited持有的公司4290万股股票于2025年11月20日10:00时至2025年11月21日10:00时止在淘宝网司法拍卖网络平台被公开拍卖。2025年11月21日，经查询淘宝网司法拍卖网络平台公开拍卖结果，公司董事、总经理、财务负责人国磊峰先生及其一致行动人西藏誉磐企业管理合伙企业参与上述司法拍卖，并竞拍取得了合计2500万股公司股份，占公司总股本的1.12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0188","BK0095","002437","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2585113235","title":"誉衡药业：大部分核心产品已进入集采目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113235","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113235?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:45","pubTimestamp":1763714713,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业11月21日在投资者关系平台上答复投资者关心的问题。截止目前，公司哪些产品遇到医院准入门槛高、医保目录进入缓慢等问题？公司大部分核心产品均已进入集采目录。部分产品由于成本、资质等问题没有进入集采，比如公司与第一三共合作的原研产品普伐他汀钠片。根据药品不同属性以及不同患者人群的需求，公司将采取更有针对性的市场推广策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100022023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","002437","BK0095","BK0188","BK0239","BK0060"],"gpt_icon":0},{"id":"2585113917","title":"誉衡药业：安脑丸适应症与安宫牛黄丸类似","url":"https://stock-news.laohu8.com/highlight/detail?id=2585113917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585113917?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:42","pubTimestamp":1763714529,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司安脑丸的功效是否类似安宫牛黄丸？价格还是比较实惠誉衡药业回复：您好！安脑丸的适应症是清热解毒，醒脑安神，豁痰开窍，镇惊熄风。用于高热神昏，烦躁谵语，抽搐惊厥，中风窍闭，头痛眩晕；高血压、脑中风见上述证候者；与安宫牛黄丸的适应症有一定类似性。安脑丸更偏重于治疗出血性和缺血性卒中，且在医生处方的前提下可以长期服用。相较于安宫牛黄丸的市场价，安脑丸价格更为实惠。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100021703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","BK0188","BK0028","BK0239","BK0095","002437"],"gpt_icon":0},{"id":"2584999757","title":"誉衡药业：产品覆盖骨科心脑血管等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584999757?lang=zh_cn&edition=full","pubTime":"2025-11-19 11:36","pubTimestamp":1763523397,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月18日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司药品在养老产业方面是否有助力和应用？誉衡药业回复：您好！公司产品主要涵盖骨科、心脑血管、糖尿病等治疗领域，上述领域相关适应症如骨关节炎、高血脂、高血糖等常见于老年群体。公司将会围绕核心治疗领域积极丰富产品管线。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900014221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0095","BK0188","BK0028","BK0239","BK0060","002437"],"gpt_icon":0},{"id":"2584678906","title":"股市必读：誉衡药业（002437）11月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584678906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584678906?lang=zh_cn&edition=full","pubTime":"2025-11-18 01:02","pubTimestamp":1763398944,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，誉衡药业报收于3.39元，下跌2.02%，换手率3.07%，成交量64.47万手，成交额2.19亿元。董秘最新回复投资者： 请问贵公司的医药电商业务开展的如何？目前该产品尚未在国内销售。预计明年根据市场情况，公司将会进行入院及开发相关工作。请董秘详细解答！当日关注点来自交易信息汇总：11月17日主力资金净流出3284.86万元，显示主力资金持续离场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800000661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0095","BK0060","BK0188","BK0077","002437","BK0239"],"gpt_icon":0},{"id":"2584237366","title":"誉衡药业：创新药是公司长期布局的方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2584237366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584237366?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:51","pubTimestamp":1763383901,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司在创新药方面有什么进展和规划？目前我国创新药规模已经赶超美国，贵公司做为创新药药企，是否规划好发展方向和投资？誉衡药业回复：您好！创新药是公司长期布局的方向，未来主要考虑通过合作、并购、BD等方式开展。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700033654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","BK0060","BK0188","BK0028","BK1574","BK0077","BK0095","BK1161","06978","159992","BK0239"],"gpt_icon":0},{"id":"2584648589","title":"誉衡药业：西格列汀二甲双胍缓释片2025年1-9月收入达2,500万元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2584648589","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584648589?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:09","pubTimestamp":1763366949,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业11月17日在投资者关系平台上答复投资者关心的问题。西格列汀二甲双胍缓释片于 2024 年 7 月正式销售，2025 年1-9 月收入达 2,500 万元左右，占公司整体收入的比例偏低。预计该产品在未来两年将处于相对较好的窗口期，我们将持续优化市场策略，促进产品在医院的开发及上量，推动销量和收入的增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700019055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0095","BK0060","BK0188","BK0077","002437","BK0239"],"gpt_icon":0},{"id":"2584369610","title":"誉衡药业：氯化钾缓释片等产品通过线上销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2584369610","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584369610?lang=zh_cn&edition=full","pubTime":"2025-11-17 15:42","pubTimestamp":1763365343,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的医药电商业务开展的如何？双十一是销售是否有热销放量？誉衡药业回复：您好！公司产品主要以院内销售为主，氯化钾缓释片、安脑丸/片等部分产品也通过线上方式进行销售，但金额还比较小。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700015629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0095","BK0239","002437","BK0188","BK0060","BK0077"],"gpt_icon":0},{"id":"2584617406","title":"誉衡药业：公司主要业务为医药制造及销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2584617406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584617406?lang=zh_cn&edition=full","pubTime":"2025-11-17 15:33","pubTimestamp":1763364793,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司地处黑龙江自贸区，是否会助力冬季东北如火如荼的冰雪经济？对于冰雪经济公司有何布局和规划？誉衡药业回复：您好！公司主要业务为医药制造及销售，与冰雪经济相关性较弱。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700014670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","159938","002437","BK0028","BK0239","BK0188","BK1574","09939","BK0077","BK1515","BK1161","BK0095"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766061175423,"stockEarnings":[{"period":"1week","weight":-0.0314},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.102},{"period":"6month","weight":0.1},{"period":"1year","weight":0.145},{"period":"ytd","weight":0.2369}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"哈尔滨誉衡药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"102900人(较上一季度减少1.25%)","perCapita":"20403股","listingDate":"2010-06-23","address":"黑龙江省哈尔滨市呼兰区利民经济技术开发区北京路29号","registeredCapital":"223202万元","survey":"　　哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是鹿瓜多肽注射液、安脑丸、安脑片、氯化钾缓释片、注射用磷酸肌酸钠、银杏达莫注射液、注射用多种维生素（12）、注射用氟尿嘧啶、注射用盐酸平阳霉素。公司核心产品市场认可度高，鹿瓜多肽注射液曾被黑龙江省医药行业协会评为“医药行业科技进步奖一等奖”、氯化钾缓释片曾被评为广东省名优高新技术产品、银杏达莫注射液曾被评为山西省名牌产品。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"誉衡药业,002437,誉衡药业股票,誉衡药业股票老虎,誉衡药业股票老虎国际,誉衡药业行情,誉衡药业股票行情,誉衡药业股价,誉衡药业股市,誉衡药业股票价格,誉衡药业股票交易,誉衡药业股票购买,誉衡药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}